SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
nancyrui
Lv3
320 积分
2022-04-01 加入
最近求助
最近应助
互助留言
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
2个月前
已完结
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2
2个月前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
2个月前
已完结
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress
2个月前
已完结
Immune‐related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity
4个月前
已完结
Clonally expanded, thyrotoxic effector CD8 + T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis
4个月前
已完结
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)
11个月前
已完结
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
11个月前
已完结
Deciphering breast cancer: from biology to the clinic
1年前
已完结
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer
1年前
已完结
没有进行任何应助
感谢
2个月前
感谢
2个月前
感谢
2个月前
感谢
2个月前
感谢,点赞,帮大忙了,么么哒
4个月前
感谢,速度真快,么么哒
4个月前
感谢,帮大忙了
11个月前
感谢,点赞,速度真快
1年前
感谢,速度真快,帮大忙了
1年前
感谢
1年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论